CoChat

Alzheimer’s disease progression by geographical region in a clinical trial setting

Open access
Henley, David B, Dowsett, Sherie A, Chen, Yun-Fei, Liu-Seifert, Hong, Grill, Joshua D, Doody, Rachelle S, Aisen, Paul, Raman, Rema, Miller, David S, Hake, Ann M, Cummings, Jeffrey · 2015 · Alzheimer's Research & Therapy
Cited by 35

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Introduction: To facilitate enrollment and meet local registration requirements, sponsors have increasingly implemented multi-national Alzheimer’s disease (AD) studies. Geographic regions vary on many dimensions that may affect disease progression or its measurement. To aid researchers designing and implementing Phase 3 AD trials, we assessed disease progression across geographic regions using placebo data from four large, multi-national clinical trials of investigational compounds developed to target AD pathophysiology. Methods: Four similarly-designed 76 to 80 week, randomized, double-blind placebo-controlled trials with nearly identical entry criteria enrolled patients aged ≥55 years with mild or moderate NINCDS/ADRDA probable AD. Descriptive analyses were performed for observed mean score and observed mean change in score from baseline at each scheduled visit. Data included in the analyses were pooled from the intent-to-treat placebo-assigned overall (mild and moderate) AD dementia populations from all four studies. Disease progression was assessed as change from baseline for each of 5 scales - the AD Assessment Scale-cognitive subscale (ADAS-cog11), the AD Cooperative Study- Activities of Daily Living Scale (ADCS-ADL), Mini-Mental State Examination (MMSE), the Clinical Dementia Rating scored by the sum of boxes method (CDR-SB), and the Neuropsychiatric Inventory (NPI). Results: Regions were heterogeneous at baseline. At baseline, disease severity as measured by ADAS-cog11, ADCS-ADL, and CDR-SB was numerically worse for Eastern Europe/Russia compared with other regions. Of all regional populations, Eastern Europe/Russia showed the greatest cognitive and functional decline from baseline; Japan, Asia and/or S. America/Mexico showed the least cognitive and functional decline. Conclusions: These data suggest that in multi-national clinical trials, AD progression or its measurement may differ across geographic regions; this may be in part due to heterogeneity across populations at baseline. The observed differences in AD progression between outcome measures across geographic regions may generalize to 'real-world' clinic populations, where heterogeneity is the norm. Trial registrations: ClinicalTrials.gov NCT00594568 – IDENTITY. Registered 11 January 2008. ClinicalTrials.gov NCT00762411 – IDENTITY2. Registered 26 September 2008 ClinicalTrials.gov NCT00905372 – EXPEDITION. Registered 18 May 2009 ClinicalTrials.gov NCT00904683 – EXPEDITION2. Registered 18 May 2009

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-015-0127-0

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 35

Metadata

Authors
Henley, D. B., Dowsett, S. A., Chen, Y.-F., Liu-Seifert, H., Grill, J. D., Doody, R. S., Aisen, P., Raman, R., Miller, D. S., Hake, A. M., & Cummings, J.
Venue
Alzheimer's Research & Therapy
Published
2015-06-25
Volume
7
Issue
1
Pages
43-43
ISSN
1758-9193 (ISSN-L)
OpenAlex
W1795834515
Cited by
35
References
7
FWCI
2.65
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Alzheimer’s disease progression by geographical region in a clinical trial setting. https://app.cochat.ai/papers/10.1186/s13195-015-0127-0
The paper
Henley, D. B., Dowsett, S. A., Chen, Y.-F., Liu-Seifert, H., Grill, J. D., Doody, R. S., Aisen, P., Raman, R., Miller, D. S., Hake, A. M., & Cummings, J. (2015). Alzheimer’s disease progression by geographical region in a clinical trial setting. Alzheimer's Research & Therapy. https://doi.org/10.1186/s13195-015-0127-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.